Price$5.32-0.76 (-12.50%)
01:45 PM07:45 PM
News · 26 weeks53-80%
2025-12-142026-06-07
Mix3590d
- SEC Filings15(43%)
- Insider10(29%)
- Other6(17%)
- Leadership2(6%)
- Earnings2(6%)
Latest news
25 items- SECFemasys Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company's portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company's FemVue device for in-office ultrasound-based evaluation. Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is focused on e
- SECSEC Form 10-Q filed by Femasys Inc.10-Q - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update. Corporate Highlights from 1Q 2026 to date Advanced initial commercial adoption of FemaSeed Complete, positioning Femasys to expand access to first-line fertility treatment through integrated, in-office care by OB/GYNs, supporting earlier intervention prior to referral to higher-cost specialty care.Launched FemaSeed Complete at ACOG 2026, advancing commercialization and expandi
- PRFemasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting, led by FemaSeed as a first-line infertility treatment. The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, whe
- SECSEC Form DEF 14A filed by Femasys Inc.DEF 14A - FEMASYS INC (0001339005) (Filer)
- SECSEC Form DEFA14A filed by Femasys Inc.DEFA14A - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the commercial launch of FemaSeed Complete, a comprehensive fertility solution that enables OB/GYNs to perform first-line insemination entirely within their own practices. An estimated 10 million women in the United States experience infertility, yet fewer than half access care, and only a very small percentage ultimately undergo IVF. At the same time, U.S. fertility rates declined again in 2025 to a record low, underscoring the growing need for ear
- PRFemasys Drives International Growth with Israeli Market Entry for Fertility Portfolio-- Partnership with AMI Technologies Positions FemaSeed® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions -- ATLANTA, April 16, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today a strategic partnership with AMI Technologies to introduce and commercialize its fertility portfolio in Israel. This collaboration marks an important step in the Company's global expansion strategy and is expected to broaden international market access and drive adoption of innovative
- SECSEC Form DEF 14A filed by Femasys Inc.DEF 14A - FEMASYS INC (0001339005) (Filer)
- INSIDERSEC Form 4 filed by Canning John Charles4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 3 filed by new insider Canning John Charles3 - FEMASYS INC (0001339005) (Issuer)
- SECFemasys Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial GrowthATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining
- SECSEC Form S-8 filed by Femasys Inc.S-8 - FEMASYS INC (0001339005) (Filer)
- SECSEC Form 10-K filed by Femasys Inc.10-K - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate UpdateATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au
- INSIDERSEC Form 4 filed by Lee-Sepsick Kathy4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Elefant Dov4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Larsen Charles4 - FEMASYS INC (0001339005) (Issuer)
FEMY FAQ
7 questionsWhat does Femasys Inc. do?
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its...Where does FEMY stock trade?
Femasys Inc. (FEMY) is listed on NASDAQ.What sector and industry is FEMY in?
Femasys Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Femasys Inc. go public?
Femasys Inc. (FEMY) completed its IPO in 2021.What are analysts saying about FEMY?
Femasys Inc. has had 3 recent analyst actions on file. The most recent action was from Laidlaw: Buy with a $650.00 price target on 2025-11-20. Recent price targets range from $650.00 to $2500.00.What companies are similar to FEMY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare FEMY side-by-side with any of them on Quantisnow.How can I track FEMY on Quantisnow?
Quantisnow aggregates Femasys Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FEMY to receive live email and push alerts on every new disclosure.